Contact Us
Drug Search Results
More Filters [+]

Denufosol

Alternative Names: denufosol, ins37217, ins3721
Latest Update: 2022-01-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: P2Y2 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Topical,Inhalant,Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Denufosol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Cystic Fibrosis|Pulmonary Fibrosis

Phase 2: Pulmonary Fibrosis|Cystic Fibrosis|Macular Edema|Retinal Detachment|Uveitis|Rhinitis, Allergic, Perennial|Cataract

Phase 1: Healthy Volunteers|Retinal Detachment

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
DEFY

P3

Terminated

Cystic Fibrosis

2011-02-01

P08640

P3

Completed

Cystic Fibrosis

2010-10-01

REACH-1

P2

Completed

Cystic Fibrosis

2010-10-01

NCT00357279

P3

Completed

Cystic Fibrosis|Pulmonary Fibrosis

2008-09-01

Recent News Events

Date

Type

Title

01/01/2022

PubMed

 Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics.

12/17/2020

PubMed

 Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions